By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Tuesday, May 4th. Please refresh for updates. Pfizer (NYSE:PFE) stock rose 0.9% after the drugmaker...
Investing.com – U.S. equities were mixed at the close on Monday, as gains in the Oil & Gas, Basic Materials and Healthcare sectors propelled shares higher while losses in the...
Investing.com – U.S. equities were mixed at the close on Tuesday, as gains in the Oil & Gas, Financials and Industrials sectors propelled shares higher while losses in the...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Sell | Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 1,135.00 | 1,165.00 | 1,116.00 | -30.00 | -2.58% | 87.79K | London | |||
| 279.00 | 287.00 | 273.40 | -6.80 | -2.38% | 1.13M | London | |||
| 357.50 | 359.00 | 351.00 | +2.50 | +0.70% | 393.17K | London | |||
| 168.10 | 178.56 | 167.40 | -13.54 | -7.45% | 40.49M | London | |||
| 401.00 | 401.00 | 399.60 | +1.20 | +0.30% | 783.49K | London | |||
| 1,285.00 | 1,293.00 | 1,265.00 | +10.00 | +0.78% | 517.19K | London | |||
| 423.00 | 424.40 | 416.10 | -3.20 | -0.75% | 1.92M | London | |||
| 289.20 | 293.95 | 287.85 | -6.45 | -2.18% | 39.84M | London | |||
| 639.00 | 639.00 | 624.00 | +7.00 | +1.11% | 110.93K | London | |||
| 155.60 | 156.00 | 153.20 | -0.40 | -0.26% | 757.68K | London | |||
| 99.71 | 101.14 | 98.30 | -2.47 | -2.42% | 32.29M | London | |||
| 135.50 | 137.45 | 134.85 | -2.60 | -1.88% | 4.80M | London | |||
| 284.00 | 287.60 | 283.50 | -3.80 | -1.32% | 3.72M | London | |||
| 233.00 | 233.80 | 230.55 | -0.25 | -0.11% | 16.40M | London | |||
| 327.20 | 338.90 | 322.90 | -1.90 | -0.58% | 724.71K | London |
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company’s proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.
